Open AccessHedgehog Pathway Inhibition
Author(s) -
Aleksandar Sekulić,
Daniel D. Von Hoff
Publication year - 2016
Publication title -
cell
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 26.304
H-Index - 776
eISSN - 1097-4172
pISSN - 0092-8674
DOI - 10.1016/j.cell.2016.02.021
Subject(s) - vismodegib , smoothened , hedgehog signaling pathway , biology , hedgehog , basal cell carcinoma , cancer research , medicine , pharmacology , microbiology and biotechnology , signal transduction , basal cell
The hedgehog (Hh) signaling pathway is aberrantly activated in a majority of basal cell carcinomas (BCC). Vismodegib and sonidegib are targeted inhibitors of Smoothened (SMO). Both drugs are approved for use in locally advanced BCC (laBCC), with vismodegib also approved for metastatic BCC (mBCC).
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom